Human medicines European public assessment report (EPAR): Galafold, migalastat, Fabry Disease, Date of authorisation: 25/05/2016, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Fabrazyme, agalsidase beta, Fabry Disease, Date of authorisation: 03/08/2001, Revision: 26, Status: Authorised

Case Medical Research ◽

10.31525/cmr-19715f1 ◽

2019 ◽

Author(s):

Keyword(s):

Fabry Disease ◽

Agalsidase Beta ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Galafold, migalastat, Fabry Disease, Date of authorisation: 25/05/2016, Revision: 9, Status: Authorised

Case Medical Research ◽

10.31525/cmr-39976c ◽

2019 ◽

Author(s):

Keyword(s):

Fabry Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Controloc Control, pantoprazole, Gastroesophageal Reflux, Date of authorisation: 11/06/2009, Revision: 11, Status: Authorised

Case Medical Research ◽

10.31525/cmr-193042d ◽

2019 ◽

Author(s):

Keyword(s):

Gastroesophageal Reflux ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Striascan, ioflupane (123i), Radionuclide Imaging,Dementia,Movement Disorders, Date of authorisation: 25/06/2019

Case Medical Research ◽

10.31525/cmr-193042a ◽

2019 ◽

Author(s):

Keyword(s):

Radionuclide Imaging ◽

Movement Disorders ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Dementia,Alzheimer Disease,Parkinson Disease, Date of authorisation: 11/12/2009, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1930425 ◽

2019 ◽

Author(s):

Keyword(s):

Alzheimer Disease ◽

Parkinson Disease ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Ribavirin Mylan (previously Ribavirin Three Rivers), ribavirin, Hepatitis C, Chronic, Date of authorisation: 10/06/2010, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1907582 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Three Rivers

Human medicines European public assessment report (EPAR): LysaKare, arginine / lysine, Radiation Injuries, Date of authorisation: 25/07/2019, Status: Authorised

Case Medical Research ◽

10.31525/cmr-18ff4a5 ◽

2019 ◽

Author(s):

Keyword(s):

Radiation Injuries ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Irbesartan Zentiva (previously Irbesartan Winthrop), irbesartan, Hypertension, Date of authorisation: 19/01/2007, Revision: 21, Status: Authorised

Case Medical Research ◽

10.31525/cmr-134bca5 ◽

2019 ◽

Author(s):

Keyword(s):

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Baraclude, entecavir, Hepatitis B, Chronic, Date of authorisation: 26/06/2006, Revision: 24, Status: Authorised

Case Medical Research ◽

10.31525/cmr-134bca4 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis B ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Human medicines European public assessment report (EPAR): Insuman, insulin human, Diabetes Mellitus, Date of authorisation: 21/02/1997, Revision: 27, Status: Authorised

Case Medical Research ◽

10.31525/cmr-133690d ◽

2019 ◽

Author(s):

Keyword(s):

Diabetes Mellitus ◽

Assessment Report ◽

European Public ◽

Human Diabetes ◽

European Public Assessment Report